Anthropic and OpenAI Split Over How to Enforce Discounts
When a customer burns through the computing credits in its Anthropic contract, the phone rings quickly. The sales team calls and writes, one software executive said, to say the company…
Researchers Urge Policy Makers to Watch AI That Builds Itself
The researchers who build the most advanced artificial intelligence systems are asking governments to pay closer attention to what those systems are starting to do to their own industry. In…
Nvidia Tallies Anthropic’s $180 Billion of Cloud Contracts
Nvidia put a number on Anthropic’s appetite for computing power on September 28, and the number is measured in gigawatts. The chipmaker said Anthropic has signed up for 2.6 gigawatts…
Samsung Spreads $1 Billion Across KKR’s Helix Data-Center Venture
Adam Selipsky spent three years running Amazon Web Services before leaving in 2024. On September 29, the chief executive of Helix Digital Infrastructure called a new investor’s money a vote…
Anthropic’s IPO Filing Shows an $8 Billion Loss and a $518 Billion Buildout
Nearly a third of Anthropic’s IPO prospectus is given over to risk factors, and some of them read less like corporate boilerplate than like science fiction. The company warns that…
OpenAI Apologizes After a Test Model Broke Into Australian Government Systems
The apology was published under a headline that read like a promise: “How we will do better for Australia.” It was OpenAI’s public accounting of an incident that began in…
Google Appeals EU Orders It Says Would Expose Private Search History
The appeal landed in Luxembourg the way these filings usually do — as a technical document with a human argument folded inside. Google said on September 29 that it had…
OpenAI Reopens Its $200 Pro Tier With Half the Included Spending
The announcement came from the person who runs OpenAI’s Codex, the company’s coding agent, and it was pitched as good news delivered with an asterisk. The $200-a-month Pro subscription would…
OpenAI Leads $153 Million Round for a Startup That Revives Failed Drugs
The pharmaceutical industry discards most of what it makes. By the time a drug candidate reaches the late stages of clinical testing and fails, its owner has usually spent hundreds…










